Insider Trading April 15, 2026 04:52 PM

Aehr Test Systems CTO Disposes $1.24 Million of Shares as Stock Nears 52-Week High

Donald P. Richmond II reduces stake after sale of 17,011 shares; company posts mixed Q3 results and records strong bookings

By Nina Shah AEHR
Aehr Test Systems CTO Disposes $1.24 Million of Shares as Stock Nears 52-Week High
AEHR

Aehr Test Systems Chief Technology Officer Donald P. Richmond II sold 17,011 shares on April 14, 2026, generating $1.24 million. The transaction occurred while AEHR stock trades close to its 52-week peak amid a dramatic 12-month rally. The company reported mixed Q3 2026 results with an EPS beat, a revenue miss, but record quarterly bookings and an expanding backlog. Analysts adjusted price targets in response to bookings momentum.

Key Points

  • CTO Donald P. Richmond II sold 17,011 shares on April 14, 2026 for $73.1764 per share, totaling $1,244,803.
  • AEHR trades near its 52-week high after a 771% one-year gain; shares quoted at $73.26 with a $2.29 billion market cap.
  • Q3 2026 showed an EPS beat of -$0.05 versus -$0.07 expected, revenue of $10.3 million below forecasts, but record quarterly bookings of $37.2 million and an effective backlog above $50 million.

Insider sale details

Donald P. Richmond II, the Chief Technology Officer of Aehr Test Systems (NASDAQ: AEHR), executed a sale of 17,011 common shares on April 14, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares traded at $73.1764 apiece, producing proceeds of $1,244,803 for the transaction.

Current trading context

The sale coincided with AEHR trading near its 52-week high of $74.72, approximately 1% below that high-water mark. Over the past year the equity has delivered an exceptional return of 771%. At the time of the filing the stock quoted at $73.26, which implies a market capitalization of $2.29 billion.

Valuation and revenue trends

InvestingPro analysis flags AEHR as appearing overvalued versus its Fair Value assessment. That view is noted alongside the company’s elevated revenue valuation multiple, even as reported revenue declined 26% to $45.26 million. These valuation metrics are highlighted as a point of concern in light of recent financial performance.

Post-sale ownership and research access

Following the disposition, Richmond still directly holds 181,512 shares of Aehr Test Systems common stock. That total includes shares that remain subject to unvested restricted stock units. For investors seeking further detail on valuation and financial metrics, a Pro Research Report covering AEHR and more than 1,400 other U.S. stocks is available on InvestingPro.

Recent operating performance

Aehr Test Systems disclosed mixed results for its fiscal Q3 2026. The company reported an earnings per share of -$0.05, outperforming the consensus forecast of -$0.07. Revenue came in at $10.3 million, short of the expected $10.8 million. Offsetting the revenue shortfall, management reported record quarterly bookings of $37.2 million, and an effective backlog that now exceeds $50 million, indicating an acceleration in demand metrics.

Analyst reactions

Following the quarterly update, analyst firm Freedom Broker raised its price target for Aehr Test Systems to $61 while maintaining a Hold rating. Lake Street increased its price target to $56 and kept a Buy rating, citing momentum in bookings as the rationale for its outlook. These adjustments reflect continuing analyst attention to the company’s order book and bookings trends.


Bottom line

The insider sale by Aehr’s CTO occurred against a backdrop of a sharply higher share price, mixed quarterly results, and strong bookings. Richmond’s remaining stake remains substantial, and analysts have updated their targets based on recent demand indicators.

Risks

  • Valuation risk - InvestingPro flags AEHR as appearing overvalued based on its Fair Value assessment and a high revenue valuation multiple, which could weigh on equity performance.
  • Revenue contraction - Reported revenue declined 26% to $45.26 million, and recent quarterly revenue missed expectations, introducing uncertainty for near-term top-line recovery.
  • Execution and demand uncertainty - While bookings are strong and backlog is growing, converting backlog into revenue and sustaining demand momentum remain material uncertainties for company performance.

More from Insider Trading

DTI President Executes Small Sale; Company Posts Resilient Q4 Revenues Apr 15, 2026 Beyond Meat CFO Executes $253K Stock Sale Amid Operational Updates and Analyst Cuts Apr 15, 2026 Ingersoll Rand Director Sells $2.68M in Stock After Exercising Options Apr 15, 2026 C3.ai Chairman Siebel Disposes $4.11M in Class A Shares After Exercising Options Apr 15, 2026 MediaAlpha Director Executes $112,891 in Stock Sales Over Three Days Apr 15, 2026